Guidance For Industry Investigator Responsibilities – Protecting The Rights, Safety, And Welfare Of Study Subjects
Contains Nonbinding Recommendations
TABLE OF CONTENTS
I. INTRODUCTION
II. OVERVIEW OF INVESTIGATOR RESPONSIBILITIES
III. CLARIFICATION OF CERTAIN INVESTIGATOR RESPONSIBILITIES
A. Supervision of the Conduct of a Clinical Investigation
1. What Is Appropriate Delegation of Study-Related Tasks?
2. What Is Adequate Training?
3. What Is Adequate Supervision of the Conduct of an Ongoing Clinical Trial?
4. What Are an Investigator’s Responsibilities for Oversight of Other Parties Involved in the Conduct of a Clinical Trial?
B. Protecting the Rights, Safety, and Welfare of Study Subjects
1. Reasonable Medical Care Necessitated by Participation in a Clinical Trial.
2. Reasonable Access to Medical Care.
3. Protocol Violations that Present Unreasonable Risks.
ATTACHMENT A: COPY OF FORM 1572.
U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)
Center for Devices and Radiological Health (CDRH)
Additional copies are available from:
Office of Training and Communication
Division of Drug Information, HFD-240
Center for Drug Evaluation and Research
Food and Drug Administration
(Tel) 301-827-4573
http://www.fda.gov/cder/guidance/index.htm or
Office of Communication, Training and Manufacturers Assistance, HFM-40
Center for Biologics Evaluation and Research
Food and Drug Administration
http://www.fda.gov/cber/guidelines.htm (Tel) 800-835-4709 or 301-827-1800 or
Office of Health and Industry Programs
Division of Small Manufacturers, International, and Consumer Assistance, HFZ-220
Center for Devices and Radiological Health
Food and Drug Administration
Tel: 1-800-638-2041
http://www.fda.gov/cdrh U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)
Center for Devices and Radiological Health (CDRH)
Procedural
October 2009
Clinical Research News
Upcoming Clinical Research Events
-
26 – 28 September 2023
Fierce Pharma
United States -
29 September – 01 October 2023
SOCRA (Society of Clinical Research Associates) -
Canada -
08 – 11 October 2023
TransCelerate BioPharma
United States -
08 – 11 October 2023
SCDM (Society of Clinical Data Management)
United States -
16 – 17 October 2023
The Conference Forum
United States -
17 – 18 October 2023
Cambridge Innovation Institute
Spain -
01 – 03 November 2023
RQA (Research Quality Association)
United Kingdom -
11 – 15 November 2023
AMIA (American Medical Informatics Association)
United States -
15 – 16 November 2023
World BI
United States -
29 – 30 November 2023
Informa
Spain
今後の臨床試験
-
NCT06049576募集明細胞腎細胞がん | ステージ III 腎細胞がん AJCC v8 | ステージ IV 腎細胞がん AJCC v8 | 肉腫様腎細胞がん
-
NCT06050057募集クッシング症候群 | 褐色細胞腫 | 副腎皮質がん | 副腎皮質疾患 | 副腎皮質腺腫 | 副腎腫瘍 | 副腎摘出;スターテス | 副腎腫瘤 | 副腎過形成 | 副腎疾患
-
NCT06051240まだ募集していません認識機能障害 | 脳腫瘍 | 認知機能の低下 | 記憶障害 | 放射線治療の副作用 | 放射線療法;合併症 | 放射線の晩期障害